New White Paper: Proactive Planning to Optimize the Use of Biomarkers in Oncology Clinical Trials
Oncology drugs developed through a biomarker-guided precision medicine design are 38% more likely to be commercialized. Yet this good news comes with critical operational considerations that can mean the difference between success and failure.
This free white paper from Pat Devitt, President, Precision for Medicine Oncology and Rare Disease, will help you:
- Pressure-test your approach to using biomarkers in clinical trials
- Understand how peers are reducing approval times
- Leverage new solutions to integrate, harmonize, and analyze multiomic data
Begin optimizing your biomarker strategy—download the white paper now.